Please note that some translations using Google Translate may not be accurately represented, and image captions and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result for using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Mary Cooley, PhD, APRN, Donna L. Berry, PhD, RN, AOCN, FAAN, and Meghan Underhill, PhD, RN, AOCNS, conduct a variety of clinical trials.
The mission of the Cantor Center is to reduce the burden of cancer through scholarly inquiry and rigorous research. The focus of the Center's research is the patient/family experience of living with a predisposition to or diagnosis of cancer, as well as survivorship issues post-treatment.
The Cantor Center's efforts focus on three major areas:
Donna L. Berry, PhD, RN, AOCN, FAAN, along with Mary Cooley, PhD, APRN, and Meghan Underhill, PhD, RN, AOCNS, conduct a variety of clinical trials. The three nurse-scientists engage direct care nurses at Dana-Farber in research relevant to their fields
of expertise, thereby creating a direct link between science and practice.
Berry conducts research on improving cancer symptom management by enhancing self-care, patient-clinician communication, and cancer treatment decision making. The Personal Patient Profile-Prostate (P3P) is the first decision aid for men with localized
prostate cancer that resulted in significantly reduced decisional conflict in a national multi-center trial. P3P is now being applied to support men in Australia as part of the TrueNTH-Australia network.
Cooley is developing a decision support system and conducting a clinical trial of symptom management in lung cancer. She is also studying smoking cessation behaviors and therapies in patients with cancer and their family members.
Underhill's research focuses on the needs of individuals at genetic high risk for cancer. Her work includes high risk breast and ovarian cancers as well as pancreatic cancer.
The UMass Boston - Dana-Farber/Harvard Cancer Center U54 Cancer Research Partnership
Mittelman Integrative Therapies Post-doctoral Research Fellowship